Cath Lab Digest - February 2008 - (Page 64)

64 CLINICAL AND INDUSTRY NEWS FEBRUARY 2008 Common Drug-Eluting Coronary Stents Appear to Have Similar Clinical Outcomes A comparison of use of the first two commercially available drug-eluting coronary stents (for the medications sirolimus and paclitaxel) among patients in “everyday clinical practice” indicates no significant differences for outcomes such as heart attack or cardiac death, according to a study in the January 30 issue of Journal of the American Medical Association. Anders M. Galløe, MD, of the University of Copenhagen, Denmark, and colleagues compared the efficacy and safety of sirolimuseluting and paclitaxel-eluting stents in a study designed to reflect everyday clinical practice. The SORT OUT II trial included 2,098 men and women treated with PCI and randomized to receive either sirolimus-eluting (n = 1,065) or paclitaxel-eluting (n = 1,033) stents at five university hospitals in Denmark. The patients were initially treated for ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina. The researchers found that the proportion of patients experiencing major adverse cardiac events, such as cardiac death, heart attack, target lesion revascularization, or target vessel revascularization, were 98 (9.3 percent) for the sirolimuseluting stent group and 114 (11.2 percent) for the paclitaxel-eluting stent group. The stent thrombosis rates were 27 (2.5 percent) in the sirolimus-eluting stent group and 30 (2.9 percent) in the paclitaxeleluting stent group. “In conclusion, the SORT OUT II trial found no statistical significant differences in the primary or secondary end points between the sirolimus-eluting stent and paclitaxeleluting stent in everyday clinical practice among patients undergoing PCI for ST-segment elevation myocardial infarction, non–STsegment elevation myocardial infarction or unstable angina pectoris, and stable angina. The rates of serious adverse events, cardiac death, acute myocardial infarction, and stent thrombosis were low, suggesting that, at least when considering 18 months of follow-up, the use of drug-eluting stents in the general population may be safe,” the authors write. In an accompanying editorial, Debabrata Mukherjee, MD, and David J. Moliterno, MD, of the University of Kentucky, Lexington, comment on the findings of Galløe and colleagues regarding the comparison of stents. “In 2008, clinicians will have additional choices of drug-eluting stents with the availability of secondgeneration devices — namely, the everolimus-eluting stent, which yielded similar or fewer major adverse cardiac events among patients as compared with the paclitaxel-eluting stent, and the zotarolimus-eluting stent, which was shown to be noninferior to the paclitaxel-eluting stent. The ongoing choice of a drug-eluting stent will likely depend on multiple factors that will include safety, effectiveness, deliverability, and — given recent cuts in reimbursement — cost of the device.” “The current literature for drugeluting stents can be challenging to interpret because of differing criteria for study enrollment, definitions for acute stent thrombosis and other clinical end points, and varied intervals of dual antiplatelet therapy and follow-up after stent implantation. Similarly, current real-world registries are usually limited by lack of valid control groups and often use historical controls. A large longitudinal database for patients receiving these various drug-eluting stents with open entry to fully capture all procedures may help determine the safest and most effective revascularization practice possible and should help guide future recommendations,” they write. ■ Source: JAMA. 2008;299[4]:409416;454-455. Terumo Partners with GHX for More Efficient Electronic Ordering Capabilities T erumo Interventional Systems, a strategic business unit of Terumo Medical Corporation (TMC), announces a new partnership between TMC and Global Health Exchange (GHX). Working with GHX and its Electronic Data Interchange (EDI) system, Terumo Interventional Systems offers an e-commerce platform with a streamlined process. Hospitals are now easily able to place orders, generate receipts, and change and track orders with Terumo. In addition, Nate Letcher, Supplier Account Manager at GHX, says that “unlike traditional Value Added Network’s (VAN) solutions, GHX is dedicated to the healthcare market.” GHX brings suppliers and hospitals together through an automated electronic ordering interface. Because GHX customizes this interface based on the specific needs of providers, hospitals can actually reduce or eliminate the need to maintain individual EDI connections to their suppliers, saving $5,000 to $30,000 per connection. Synchronization also helps to reduce purchase order errors that may result in costly discrepancies for both buyers and sellers. “In addition to needing to increase efficiencies, hospitals are under increasing pressure to lower costs and decrease manual errors,” says Rick Larrieu, Terumo CIO. “By offering an integrated ordering system, hospitals are able to see an immediate cost-savings benefit on top of the improved order-to-invoice process.” Terumo believes that this partnership with GHX will enable it to strengthen relationships with its customers, improve efficiencies and ensure quality throughout the entire electronic ordering process. Among the first to utilize GHX’s services for Terumo orders was Florida Hospital. Teri Long, Florida’s EDI Information Systems Coordinator, commented that its relationship with GHX has been a success in terms of both timesavings and error reduction. “GHX is our primary VAN system, because we can depend on them to keep things running smoothly,” says Long. Even as Florida Hospital has grown with more campuses and new vendors, they have not had to expand their purchasing department partly because of GHX’s involvement. According to Long, “They (GHX) do the programming for us, which helps us coordinate our unique requirements with the vendor’s needs. GHX makes electronic ordering easier for everyone involved.” For more information, customers can contact Terumo Interventional Systems by calling its Inside Sales Customer Care Team at 800-862-4143 or by visiting www.terumois.com. http://www.terumois.com

Table of Contents Feed for the Digital Edition of Cath Lab Digest - February 2008

Cath Lab Digest - February 2008 Bay Regional Medical Center ENDEAVOR IV: A Zotarolimus-Eluting Stent Versus a Paclitaxel-Eluting Stent in a Randomized Clinical Trial A 3D CT Vessel “Roadmap” Over Live Fluoroscopy for Chronic Total Occlusions Contents Clinical Editor’s Corner An Evaluation of Cath Lab Turnaround Time Commentary: An Evaluation of Cath Lab Turnaround Time Excerpts from Chapter 19. STEMI Interventions – Future Perspectives The Potential Clinical Utility of Intravascular Ultrasound Guidance in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents The Ten-Minute Interview with…Debbie Charlton, RN The Society of Invasive Cardiovascular Professionals (SICP) at Transcatheter Cardiovascular Therapeutics (TCT) 2007 The Cath Lab is a Business: Do You Have the Knowledge to Stay Afloat? Incidence and Predictors of Vascular Complications after Invasive Coronary Procedures: A Prospective Analysis Ask the Clinical Instructor: A Q&A Column for those New to the Cath Lab Volunteer Survey SICP* Section Meetings Calendar What Do You Think? CEU Education Center Clinical & Industry News Classifieds Advertisers Index

Cath Lab Digest - February 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.